Radar · Industry landscape · South Korea
Life Sciences Landscape of South Korea
1,331 Life Sciences companies in South Korea, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about and where the research is going. Updated August 2026.
1,331companies tracked
$5.4Bdisclosed funding
8hiring right now
293events · 24 months
≥84,512news articles · 12 months
Who leads Life Sciences in South Korea
Shows the top‑ranked life‑sciences firms in South Korea by size, funding, hiring activity and media coverage, noting 1,331 companies tracked and that 153 have disclosed a funding round.
open roles
Hiring now
ranked by live open roles
- 01
Astrion10last posted Jun 2026
- 02
AMT Engineering7last posted Jun 2026
- 03
Ownist2last posted Jun 2026
- 04
NGeneBio1last posted Apr 2026
- 05
G + FLAS Life Sciences1last posted Feb 2026
- 06
AbTis1last posted Sep 2025
- 07
Orum Therapeutics1last posted Apr 2026
- 08
IMB Dx1last posted May 2026
8 companies hiring · 0 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
Cellid$2.4BSeries A · Jan 2016
- 02
Genexine$233MPost IPO · Mar 2018
- 03
D&D Pharmatech$215.5MPost IPO · Jun 2025
- 04
- 05
MedPacto$106.2MPost IPO · Dec 2020
- 06
Curocell$82.4MSeries D · Jan 2022
- 07
Standigm$69.7MSeries C · Jul 2021
- 08
CHA Biotech$67.8MPost IPO · Jan 2026
153 companies with disclosed rounds · $5.4B total
revenue
Revenue leaders
official filings first, else latest snapshot
- 01
Boryung$701.5MFY2024 filing
- 02
Dong-A ST$492.4MFY2022 filing
- 03
SK biopharmaceuticals$344.4MFY2024 filing
- 04
Clinical$232.8MFY2024 filing
- 05
Seegene Technologies$217.1MFY2024 filing
- 06
Kolon Life Science$142.8MFY2015 filing
- 07
ABL Bio$24.2MFY2024 filing
- 08
Genome & Company$13.4MFY2021 filing
19 companies with a revenue figure
headcount
Largest teams
ranked by tracked headcount
- 01
Osstem Implant2,291tracked employees
- 02
- 03
- 04
Kolmar BNH512tracked employees
- 05
- 06
- 07
JEISYS Medical197tracked employees
- 08
hlb group191tracked employees
47 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
Cytogen17.7%56 tracked events
- 02
Samsung Bioepis15.1%48 tracked events
- 03
- 04
- 05
Daewoong Pharmaceutical4.7%15 tracked events
- 06
Hugel4.1%13 tracked events
- 07
- 08
317 tracked events across 62 companies
web reach
Most-used apps
the sites in this sector the web visits most
- 01
pilgramtop 500kpillgram.kr
- 02
bionicstop 500kbionicsro.co.kr
- 03
RnDcircletop 500krndcircle.io
- 04
NeoBiotechtop 500kneobiotech.co.kr
- 05
Macrogentop 500kmacrogen.com
- 06
amo labtop 1Mamo-lab.com
- 07
Cellonixtop 1Mcellonix.co.kr
- 08
EzBiocloudtop 1Mezbiocloud.net
284 companies here run a site with a measured audience · 10 of them sit inside the web’s top million
articles
In the news
Prism news coverage, last 12 months
- 01
Samsung Medison≥31articles in the window
- 02
- 03
- 04
- 05
- 06
Bridge Biotherapeutics≥11articles in the window
- 07
- 08
33 of these companies drew sector coverage in the window
Radar
See all 1,331 Life Sciences companies in South Korea
Filter by funding, headcount, hiring and location, and export the list.
How the Life Sciences ecosystem in South Korea grew, 2016–2025
Lists the annual count of new life‑sciences companies founded from 2016 to 2025, highlighting a peak of 130 firms in 2019 and only one new firm in 2025.
Companies founded / year
new Life Sciences companies in South Korea
20162025
peak 130 in 2019
Companies raising / year
with a disclosed round that year
20162025
peak 29 in 2022
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $523.6M in 2018
Where Life Sciences companies in South Korea are based
Identifies the cities where life‑sciences firms are located, with Seoul hosting the most (481) followed by Seongnam‑Si (124) and Daejeon (59).
Hub 01
Seoul
481 Life Sciences companies
59% of the Life Sciences companies across these hubs
481companies
$3.5Bdisclosed funding
4hiring now
Hub 02
Seongnam-Si
124 Life Sciences companies
15% of the Life Sciences companies across these hubs
124companies
$846.9Mdisclosed funding
1hiring now
generated artwork
Hub 03
Daejeon
59 Life Sciences companies
7% of the Life Sciences companies across these hubs
59companies
$275.5Mdisclosed funding
1hiring now
Hub 04
Suwon-Si
56 Life Sciences companies
7% of the Life Sciences companies across these hubs
56companies
$192Mdisclosed funding
1hiring now
generated artwork
Hub 05
Incheon
31 Life Sciences companies
4% of the Life Sciences companies across these hubs
31companies
$80Mdisclosed funding
Hub 06
Yuseong District
25 Life Sciences companies
3% of the Life Sciences companies across these hubs
25companies
$167.3Mdisclosed funding
Hub 07
Daegu
22 Life Sciences companies
3% of the Life Sciences companies across these hubs
22companies
$42.5Mdisclosed funding
Hub 08
Busan
22 Life Sciences companies
3% of the Life Sciences companies across these hubs
22companies
$27.5Mdisclosed funding
The Life Sciences market map of South Korea: what these companies actually do
Breaks down the product categories these firms develop, showing enterprise tech as the largest segment (913 firms) and that physical commerce is the most common revenue model (832 firms).
- Enterprise Tech913 companies · $5.2B raised · 6 hiring
- Biopharmaceuticals379 companies · $4.5B raised · 2 hiring
- Medical Devices314 companies · $156.1M raised
- Deep Tech167 companies · $436.4M raised · 2 hiring
- Enterprise Software117 companies · $482.8M raised · 1 hiring
- Consumer Digital114 companies · $84.1M raised · 1 hiring
- In Vitro Diagnostics78 companies · $150.2M raised · 2 hiring
- Cancer Immunotherapy50 companies · $532.1M raised · 1 hiring
- Neurodegenerative Diseases Drugs36 companies · $394.7M raised
- Chronic Disease Management34 companies · $34.7M raised
- IoT in Healthcare33 companies · $24.6M raised
- At Home Diagnostics31 companies · $24.6M raised
Monetization
How Life Sciences companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Physical Commerce832
E-Commerce - Product688
Subscription293
Fee-For-Service174
Commission on Transaction30
Advertising19
E-Commerce - Service16
Licensing1
Funding, M&A and the deals moving Life Sciences in South Korea
Counts corporate events over the past two years, recording 293 events including earnings releases (49), company announcements (47) and funding rounds (42).
Earnings 49Announcement 47Funding 42Leadership 40Contracts 35M&A 26IPO 14Regulatory 14Lawsuit 8Capital 5
- FundingGalux Closes $29M in Series B Funding for AI-Driven Protein Drug Design2026-02-12
- Funding1ST Biotherapeutics closes oversubscribed $21.8M Series D led by Smilegate Investment.2026-02-01
- FundingShaperon, a Tokyo-based company providing a compliance AI platform for regulated industries, has raised ¥730 million in Series B funding, bringing its total funding to ¥1.23 billion.2026-01-19
- FundingHanwha General Insurance and Hanwha Life Insurance will participate in CHA Biotech’s third-party rights issuing, purchasing new shares of the biopharmaceutical firm worth 70 billion won and 30 billion won, respectively.2026-01-16
- FundingLabInCube Secures Strategic Investment from MetaBioMed to Expand MOF Technology into Medical Materials2026-01-11
- M&ASouth Korean e-Clinical tech firm CRScube acquired US counterpart Mednet to expand its presence in the North American clinical trials market.2025-12-22
- FundingBasgenBio also said it was selected for the government’s DIPS 1000+ initiative, which offers up to 1.1 billion won over three years through commercialization and R&D support, and that it has closed a 3.0 billion won financing with CKC Venture Capital, Pathfinder H and HLB bioStep participating.2025-12-22
- Fundingtoday announced that it secured 145 billion KRW (approximately US$100 million) in convertible preferred stock investments.2025-12-18
- M&AEli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a pact with ABL Bio.2025-11-21
- M&ALilly’s recent deals, which includes a $1.3bn acquisition of RNA-based gene therapy developer Rznomics in May 2025.2025-10-27
Mergers and acquisitions
Deals from the last 24 months where a Life Sciences company in South Korea was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| $1.3B | — | 2026-01-08 | ||
| undisclosed | Announced | 2026-01-01 | ||
| undisclosed | — | 2025-12-22 | ||
| $2.6B | Announced | 2025-11-21 | ||
| Parataxsis Holdings | undisclosed | Announced | 2025-07-28 | |
| undisclosed | Completed | 2025-07-02 |
Who is listing, hiring leaders, launching and winning work
Details specific event types such as IPO filings, leadership changes and contract wins for the sector’s companies.
IPO pipeline
7 companies listed or filing · last 24 months
Leadership moves
10 tracked people moves · last 12 months
Contract wins
24 customer wins · last 24 months
SK Plasmawon ProturkMar 2026
Progenwon governmentJul 2025
Regulatory & litigation
13 regulatory events · 9 tracked suits · 24 months
- regeneron, samsung bioepis v N, ACivil · SettledApr 2026
- progen v Ecuadorian Electric Corporation, CelecRICO litigation over failed Quevedo III and Salitral power generation projects · FiledMar 2026
Earnings pulse
companies reporting results · last 24 months
18 companies reporting43 company-quarters trackedbeat 6miss 0in line 0
Half of these companies grew revenue faster than +16.7%, half slower.
Who is building Life Sciences in South Korea
Profiles the founders and CEOs of the sector, noting 781 individuals across 674 firms, with Seoul National University appearing most often (20 alumni).
Founders and chief executives12 of 781, from the best-funded companies on this page
ex-CHA Biotech, LG Life Sciences, Hanwha Chemical. Yonsei University BS 1997 & MS 2000
Standigm, ex-Samsung Electronics, ex-University Of Pittsburgh School Of Medicine, Seoul National University, 2004
Abl Bio, ex-Hanwha Biologics, ex-Pharmabcine, Stanford University School of Medicine, 2000
Illimis Therapeutics, ex-Deargen, ex-Neuramedy, 한국과학기술원 / KAIST, 2013
Rokit Healthcare, ex-Celltrion Healthcare, ex-Tyco, 고려대학교, 1979
Ex- Logos Biosystem, Solborn Investment, Medy Tox. Seoul National University M.Sc 1997, Korea Advanced Institute of Science and Technology MBA 2002
ex-Asan Medical Center. Hanyang University MBA 2006
Ex- Korean Society of Gene and Cell Therapy, National Research Foundation of Korea. Cornell University PhD
ex-CJ CheilJedang. Korea University PhD 2006
Where the founders studied
alma mater on record for 51 of 781 founders
Seoul National University20
Korea University5
University of California (Berkeley)4
Stanford University3
Yonsei University3
Cornell University3
University of Toronto2
Massachusetts Institute of Technology2
Radar
Look up the people behind Life Sciences companies in South Korea
Search founders, executives and operators by company, role and location.
Who funds Life Sciences in South Korea
Summarizes investment activity, citing 302 funding rounds since 2016 from 369 investors and an average round size of $9.9 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| KB Investment | 23 | 13 | Apr 2026 |
| DSC Investment | 18 | 4 | Dec 2025 |
| Smile Gate Investment | 16 | 9 | Jan 2026 |
| Atinum Investment | 16 | 7 | Mar 2026 |
| Korea Investment Holdings | 16 | 7 | Apr 2026 |
| LB Investment | 16 | 2 | Jul 2025 |
| Company K Partners | 15 | 7 | Dec 2025 |
| Time Polio Asset Management | 14 | 8 | Oct 2025 |
| QUAD | 14 | 5 | Jul 2025 |
| IMM Investment | 13 | 5 | Dec 2025 |
Stage mix · rounds since 2016
Seed & Angel93
Series A–B144
Series C+ / PE30
Grants, debt & other35
The typical round is $9.9M — half were bigger, half smaller.
The biggest Life Sciences funding rounds in South Korea
Highlights the biggest disclosed funding deals, including D&D Pharmatech’s $137.1 million Series B round, and lists ten large recent rounds.
| Company | Round | Size | When | Backers |
|---|---|---|---|---|
| Series B | $137.1M | Aug 2019 | Smile Gate Investment, InterVest, Magna +2 more | |
| Series C | $65M | Jun 2018 | DS, QUAD, Hana Financial Group | |
| Series B | $54M | Jun 2021 | IMM Investment, KDB Investment, Atinum Investment +2 more | |
| Series C | $51M | Oct 2021 | Praxis Capital, DS, Kudos Ventures +1 more | |
| Series C | $45M | Feb 2022 | Daily Partners, IMM Investment, SBI Mutual Fund +10 more | |
| Series C | $44.5M | Mar 2021 | SKS Private Equity, Daishin Securities, InterVest +7 more | |
| Series B | $42M | Jul 2025 | DSC Investment, WOORI Venture Partners, Korean Development Bank +15 more | |
| Series A | $40M | Feb 2019 | — | |
| Series C | $37.1M | Sep 2020 | STIC Ventures, Atinum Investment, DS +9 more | |
| Series C | $33.1M | Nov 2018 | Daily Partners, Smile Gate Investment, Miraeassetsecuritiesus +3 more |
Venture round sizes · 2023–2025
<$1M5
$1–10M15
$10–50M17
$50–250M0
>$250M0
37 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
Series D$20.3MApr 2026
Series B$15MApr 2026
Post IPO$5.8MApr 2026
Post IPO$42.1MMar 2026
Series C$23.5MMar 2026
Series C$9.9MMar 2026
Series B$9.9MMar 2026
Series B$8.2MMar 2026
What the news says about Life Sciences in South Korea
Counts media coverage, reporting 84,512 news articles in the last year and noting the most frequently covered topics such as international political relations and trade policies.
News volume
Life Sciences coverage across South Korea · articles per quarter
2021Q22026Q1
peak ≥23,508 in 2025Q1 · ≥84,512 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 62% → 60%, negative 35% → 37% across 2021–2025.
What the coverage is about
The subjects that dominate Life Sciences news in South Korea. The arrow shows whether each one is being written about more or less than a year ago.
- International political relations≥23,168→-4%
- Security and defense policies≥18,082▼-13%
- International relations and diplomacy≥15,607▼-18%
- Trade policies and agreements≥12,105▲+70%
- International sports competitions≥11,736▲+29%
- Cryptocurrency impact on forex markets≥8,137▲+102%
- Cybersecurity and cyber warfare≥6,481▼-29%
- Military technology advancements≥6,423▼-28%
- Olympic games coverage≥5,922▼-15%
- New product launches and innovations≥5,015▲+34%
Most-covered companies · last 12 months
- ≥31
- ≥24
- ≥21
- ≥14
- ≥12
- ≥11
- ≥5
- ≥5
- ≥5
- ≥5
33 Life Sciences companies here were named in the news over this period.
Prism
Watch Life Sciences coverage in South Korea as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
bilateral trade+47%trade facilitation commitments+43%summit diplomacy+74%stablecoin fx impact+597%oil price volatility+463%bilateral trade terms+42%study overseas+128%overseas study+100%trade finance+51%world cup+255%
aircraft wreckage-88%aircraft emergency procedures-90%flight safety measures-86%olympic team selections-42%korean dmz clashes-55%
The pressures the press keeps returning to
Three recurring angles in South Korea Life Sciences coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
≥148,736 articles touch this dimension · 51.4% critical tone
20212025
signals: tariff negotiations, cuban missile crisis, free trade deals
Funding Momentum ▲ rising
≥23,679 articles touch this dimension · 43.9% critical tone
20212025
signals: quarterfinals, world cup, pre-ipo valuation
Growth ▲ rising
≥93,004 articles touch this dimension · 32.2% critical tone
20212025
signals: gdp growth rate, gdp acceleration, economic output growth
Life Sciences jobs in South Korea: who is hiring and what they ask for
Reports job posting activity, indicating zero postings in the past twelve months from one employer.
0postings · last 12 months
1postings tracked overall
1employers advertising
Most advertised titles
- 1
What Life Sciences research is working on
Summarizes academic output, with 53,147 papers total and categories like opportunities (23,660 papers) and common problems (4,958 papers).
How this field talks about itself
Life Sciences papers (gold) against all published research (grey)
Descriptive40.2% · 17.7%2.3×
Promising30.4% · 36.9%0.8×
Breakthrough14.1% · 25.9%0.5×
Problem-identifying8.3% · 10.1%0.8×
Cautionary3.5% · 4.6%0.8×
Comparative2.4% · 3.8%0.6×
Life Sciences literature runs 2.3× more “descriptive” than science at large (40.2% vs 17.7% baseline).
How the work is done
Empirical48.8%
Reviews37.2%
Methods-led11.2%
Position pieces2.2%
Theoretical0.6%
How the research reads
80% positive · 16% neutral · 4% negative, across 53,147 papers.
The institutions behind the field
- 87k
- 75k
- 61k
- 49k
- 43k
- 38k
ranked by how often their work is cited
Researchers who shaped it
Ahmad Almilaji · Reiki Nishimura · Tomofumi Osako · Yasuyuki Nishiyama · Rumiko Tashima · Masahiro Nakano · Glenn R. Gibson · Gregor Reid
The most-cited breakthroughs
- Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity · 9k cites
- In situ click chemistry generation of cyclooxygenase-2 inhibitors · 8k cites
- U1 snRNP regulates cancer cell migration and invasion in vitro · 7k cites
- Comprehensive molecular profiling of lung adenocarcinoma · 6k cites
- Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signal · 6k cites
Common problems researchers identify4,503 papers · 7 recurring themes
Problems · theme 01
Sustainable Biofuel and Biomass Production
781 papers · 17.3% of this block
▲ +26% share2022→2025 share of research on this subject
Challenges in using microbes and plant systems for renewable energy and biorefinery applications.
Biofuel · Synthetic biology · Biomass · Biorefinery
“A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application”
781 of these papers raise it as a problem
Problems · theme 02
Food Safety and Processing Risks
757 papers · 16.8% of this block
▲ +49% share2022→2025 share of research on this subject
Issues surrounding microbial hazards, nutritional quality, and health impacts of modern food processing.
Food safety · Food processing · Food products · Human health
“Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures”
757 of these papers raise it as a problem
Problems · theme 03
Gene Expression and Cell Culture Limits
711 papers · 15.8% of this block
▼ -32% share2022→2025 share of research on this subject
Barriers in mRNA, gene regulation, and cell‑culture technologies for therapeutic and veterinary development.
Messenger RNA · Gene · Cell culture · Gene expression
“Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research”
711 of these papers raise it as a problem
Problems · theme 04
Crop Nutrition and Food Security
693 papers · 15.4% of this block
▲ +24% share2022→2025 share of research on this subject
Problems in fertilisation, nutrient uptake, and breeding strategies to sustain global food supplies.
Agriculture · Crop · Food security · Germplasm
“Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants”
693 of these papers raise it as a problem
Problems · theme 05
Plant Disease and Pest Management
691 papers · 15.3% of this block
▲ +27% share2022→2025 share of research on this subject
Complexities of host‑pathogen interactions and integrated approaches to control fungal and insect threats.
Fungicide · Integrated pest management · Host · Disease management
“Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens”
691 of these papers raise it as a problem
Problems · theme 06
Antimicrobial Resistance Across Sectors
447 papers · 9.9% of this block
▲ +8% share2022→2025 share of research on this subject
Widespread resistance issues linking human, animal, and environmental antimicrobial use.
Antibiotic resistance · Antimicrobial · Antibiotics · Drug resistance
“Antimicrobial resistance in humans, livestock and the wider environment”
447 of these papers raise it as a problem
Problems · theme 07
Miscellaneous Biological and Chemical Topics
423 papers · 9.4% of this block
▼ -32% share2022→2025 share of research on this subject
Diverse interdisciplinary studies lacking a clear thematic focus.
Order · NAD+ kinase · Human being · Sodium
“Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar”
423 of these papers raise it as a problem
Cautions1,765 papers · 7 recurring themes
Cautions · theme 01
Cellular Toxicity and Oxidative Stress
379 papers · 21.5% of this block
▼ -21% share2022→2025 share of research on this subject
Caution about in‑vitro and in‑vivo models revealing stress responses to contaminants.
In vivo · Flow cytometry · In vitro · Oxidative stress
“Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells”
379 of these papers raise it as a problem
Cautions · theme 02
Genomic Selection in Plant Breeding
257 papers · 14.6% of this block
▲ +26% share2022→2025 share of research on this subject
Need for careful implementation of genomic tools to improve crop traits.
Agriculture · Selection · Production · Trait
“Genomic selection in plant breeding: from theory to practice”
257 of these papers raise it as a problem
Cautions · theme 03
Feed Additives and Animal Health
245 papers · 13.9% of this block
▼ -19% share2022→2025 share of research on this subject
Risks and benefits of novel feed compounds for livestock performance and welfare.
Feed additive · Animal feed · Feed conversion ratio · Health benefits
“Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production”
245 of these papers raise it as a problem
Cautions · theme 04
Food Contaminants and Regulatory Safety
240 papers · 13.6% of this block
▲ +21% share2022→2025 share of research on this subject
Evaluations of emerging food additives and contaminants with attention to consumer health.
Food safety · Hygiene · Contamination · Food contaminant
“Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters”
240 of these papers raise it as a problem
Cautions · theme 05
DNA Damage and Repair Mechanisms
239 papers · 13.5% of this block
▼ -33% share2022→2025 share of research on this subject
Potential pitfalls in interpreting gene‑expression and repair pathways in disease contexts.
Gene · DNA damage · DNA repair · Gene expression
“Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations”
239 of these papers raise it as a problem
Cautions · theme 06
Antibiotic Use and Co‑Selection Pressures
206 papers · 11.7% of this block
▲ +8% share2022→2025 share of research on this subject
Concerns about combined resistance drivers from antibiotics, biocides, and metals.
Antibiotic resistance · Antibiotics · Antimicrobial · Bacteria
“Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses”
206 of these papers raise it as a problem
Cautions · theme 07
Pesticide Resistance Management
199 papers · 11.3% of this block
▲ +20% share2022→2025 share of research on this subject
Challenges in designing dose strategies to mitigate evolving pest resistance.
Pesticide · Integrated pest management · PEST analysis · Biological pest control
“The use of fungal entomopathogens as endophytes in biological control: a review”
199 of these papers raise it as a problem
Opportunities22,038 papers · 7 recurring themes
Opportunities · theme 01
Advanced Antibody and Imaging Techniques
1,044 papers · 17.4% of this block
▼ -22% share2022→2025 share of research on this subject
Promising uses of fluorescent antibodies and flow cytometry for in‑vivo diagnostics.
Antibody · In vivo · Fluorescence · Flow cytometry
“Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom”
Opportunities · theme 02
Gene Modulation for Disease Therapy
1,032 papers · 17.2% of this block
▼ -30% share2022→2025 share of research on this subject
Opportunities in targeting gene expression to control apoptosis and tumor growth.
Downregulation and upregulation · Apoptosis · Gene knockdown · Cell growth
“Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc”
Opportunities · theme 03
Functional Plant‑Based Foods
878 papers · 14.6% of this block
▲ +79% share2022→2025 share of research on this subject
Development of health‑promoting ingredients and antioxidants from plant sources.
Health benefits · Functional food · Ingredient · Antioxidant
“Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives”
Opportunities · theme 04
Epigenetic and RNA‑Based Diagnostics
823 papers · 13.7% of this block
▼ -32% share2022→2025 share of research on this subject
Innovations in DNA methylation profiling and RNA detection for disease monitoring.
Gene · DNA methylation · Messenger RNA · DNA damage
“Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders”
Opportunities · theme 05
Novel Antimicrobials and Biocontrol Agents
809 papers · 13.5% of this block
▲ +24% share2022→2025 share of research on this subject
Exploration of plant‑derived compounds and postbiotic products to combat resistance.
Antimicrobial · Antibiotic resistance · Biological pest control · Bacteria
“Plants as sources of new antimicrobials and resistance-modifying agents”
Opportunities · theme 06
Genetic Improvement of Crop Traits
717 papers · 11.9% of this block
▼ -36% share2022→2025 share of research on this subject
Leveraging germplasm and quantitative trait loci for yield and quality enhancements.
Germplasm · Trait · Quantitative trait locus · Selection
“Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield”
Opportunities · theme 07
Sustainable Biomass and Biofuel Strategies
697 papers · 11.6% of this block
▲ +31% share2022→2025 share of research on this subject
Integrating microbial fermentation and agri‑food by‑products for circular bioeconomy solutions.
Biomass · Sustainability · Agriculture · Biofuel
“Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health”
Which of these themes are growing fastest
Tracks the changing share of research themes worldwide from 2022 to 2025.
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Food Safety and Processing Risks▲+49%
Plant Disease and Pest Management▲+27%
Sustainable Biofuel and Biomass Production▲+26%
Crop Nutrition and Food Security▲+24%
Antimicrobial Resistance Across Sectors▲+8%
Miscellaneous Biological and Chemical Topics▼-32%
Gene Expression and Cell Culture Limits▼-32%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Genomic Selection in Plant Breeding▲+26%
Food Contaminants and Regulatory Safety▲+21%
Pesticide Resistance Management▲+20%
Antibiotic Use and Co‑Selection Pressures▲+8%
Feed Additives and Animal Health▼-19%
Cellular Toxicity and Oxidative Stress▼-21%
DNA Damage and Repair Mechanisms▼-33%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Functional Plant‑Based Foods▲+79%
Sustainable Biomass and Biofuel Strategies▲+31%
Novel Antimicrobials and Biocontrol Agents▲+24%
Advanced Antibody and Imaging Techniques▼-22%
Gene Modulation for Disease Therapy▼-30%
Epigenetic and RNA‑Based Diagnostics▼-32%
Genetic Improvement of Crop Traits▼-36%
Prism
Go deeper on Life Sciences research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Life Sciences in South Korea beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news and research trackers, covering South Korea. Counts are of companies we track, not of every company that exists. Updated August 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.